Last reviewed · How we verify

NCT05039437

Development of Green Mei Products for the Prevention of Metabolic Syndrome

Completed NA Last updated 9 September 2021
What this trial tests

NA trial testing MGF-4 in Hypertension in 50 participants. Completed in 31 December 2019.

Timeline
15 June 2019
Primary endpoint
1 December 2019
31 December 2019

Quick facts

Lead sponsorChung Shan Medical University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment50
Start date15 June 2019
Primary completion1 December 2019
Estimated completion31 December 2019
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chung Shan Medical University

Who can join

Adults 20 to 70, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the antihypertensive effects of Mei-Gin formula-4 (MGF-4) and Mei-Gin formula-7.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other Chung Shan Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05039437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing